Please assess the completion status of the following clinical trial:

Trial Title: Moderate to Persistent Asthma in the Obese Subject

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* moderate persistent asthma as defined daily symptoms, nocturnal awakenings \>1 time/week but not daily, daily short-acting beta agonist usage~* pre-bronchodilator Force expiratory volume (FEV1)\>55% but \<90%.~* Subjects must be on controller therapy for asthma with ICS for at least one month prior to enrollment.~* methacholine testing that causes a drop in the FEV1 of 20% (8mg/ml off ICS or 16mg/ml) on ICS within 6 months prior to entry~* physician diagnosis of asthma for at least one year prior to study enrollment.~* Obesity defined as BMI greater than 30.~* subjects must have an Asthma Control Questionnaire (ACQ) score \>1.25 on the Juniper Asthma Control Questionnaire (indicating poor asthma control),~* require daily medications for asthma and be compliant with study related medications.~Exclusion Criteria:~* Subjects must not have been intubated in the last 5 years or unstable asthma symptoms resulting in significant loss or work or school~* upper or lower respiratory tract infection within 1 month of the study~* use of antibiotics within 4 weeks of the study~* use of oral glucocorticoids within 4 weeks~* use of theophylline~* smoking history greater than 10 pack years or any cigarette use within the past two years~* significant non-asthma pulmonary disease or other medical problems~* Subjects planning to undergo gastric bypass surgery within 4 months of the enrollment date will be excluded since weight loss is a potential confounder of asthma control~* Pregnant women will also be excluded

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- leukotriene receptor antagonist (LTRA) montelukast (Type: ACTIVE_COMPARATOR): Montelukast (LTRA) administered with moderate dose of inhaled steroid
- Sugar Pill (Type: PLACEBO_COMPARATOR): High dose of inhaled steroid administered with sugar pill

Based on this trial design, predict the completion outcome and termination type (if applicable).